A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

  • STATUS
    Recruiting
  • End date
    Dec 23, 2024
  • participants needed
    30
  • sponsor
    Shanghai Miracogen Inc.
Updated on 7 October 2022

Summary

The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to determine the recommended phase II dose (RP2D) of combination therapy; , and to evaluate the preliminary efficacy, pharmacokinetics, and immunogenicity of combination therapy in the targeted study population.

Details
Condition Advanced Malignant Solid Tumors
Treatment MRG002+HX008
Clinical Study IdentifierNCT05338957
SponsorShanghai Miracogen Inc.
Last Modified on7 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Willing to sign the informed consent form and follow the requirements specified in the protocol
Aged 18 to 75 (including 18 and 75), both genders
Life expectancy ≥ 12 weeks
Patients with histopathological or cytological confirmed HER2-expressed advanced solid tumors, and with at least one measurable lesion according to the Response Criteria in Solid Tumors (RECIST v1.1)
The score of ECOG for performance status is 0 or 1
The toxicity of previous anti-tumor treatment has recovered to ≤ Grade 1 as defined by NCI-CTCAEv5.0
No severe cardiac dysfunction
Organ functions must meet the basic requirements
Cumulative dose of anthracycline ≤ 450 mg/m2 doxorubicin or its equivalent

Exclusion Criteria

Prior treatment with chemotherapy, biological therapy, immunotherapy, radiotherapy, investigational drugs, attenuated live vaccines, immunomodulators, CYP3A4 inhibitors/inducers, antibody-drug conjugates, etc
Treatment with immune checkpoint inhibitors or tumor vaccines within 60 days prior to the first dose
Treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study period
History of severe cardiac disease
Poorly controlled hypertension and hyperglycemia
Presence of peripheral neuropathy ≥ Grade 2
History of moderate or severe dyspnea at rest due to advanced malignant tumor or its complications or severe primary pulmonary disease, or current need of continuous oxygen therapy, or current interstitial lung disease or pneumonia
Central nervous system metastasis
Received major surgery within 4 weeks prior to the first dose without complete recovery
History of hypersensitivity to any component of MRG002 or HX008 or known history of hypersensitivity of ≥ Grade 3 to macromolecular protein products/monoclonal antibodies
Evidence of active infection
History of primary immunodeficiency or autoimmune disease
Female patients with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 6 months after the last dose of study treatment
Previous history of other primary malignancies
Other conditions inappropriate for participation in this study, as deemed by the investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note